课题基金 / 基金详情

Colorectal Cancer: Characterization of a new Cre-LoxP Model

Colorectal Cancer: Characterization of a new Cre-LoxP Model
结直肠癌:新 Cre-LoxP 模型的表征
批准号:
9307305
负责人:
SHARAD KHARE
金额:
$6.08万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-03-15 至 2019-02-28

项目摘要

项目成果

SHARAD KHARE的其他基金

相似基金

相关文献

中文摘要
翻译
结直肠癌(CRC)是美国癌症相关死亡的主要原因之一。在
英文摘要
Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality in the United States. In our recent reports, we demonstrated tumor promoting role of Sprouty2, an endogenous suppressor of receptor tyrosine kinase (RTK)/ Mitogen Activated Protein Kinase (MAPK) signaling pathways in colorectal cancer (CRC). In order to establish in vivo role of Sprouty2 in cancer we recently generated Sprouty2F/F mouse in our laboratory. The objectives of this RO3 application are to characterize the model and study the effect of embryonic (Sprouty2F/F-Villin Cre) and postnatal (Sprouty2F/F-Villin CreERT2) deletion of Sprouty2 on CRC progression. Our rationale for these studies is that establishing in vivo role of Sprouty2 gene in CRC would allow us to submit a mechanistic RO1 application. In vitro studies from our laboratory utilizing cell culture models, orthotopic and metastasis mouse models demonstrated oncogenic potential of Sprouty2 in CRC. In preliminary studies, we also established that TAT dependent Sprouty2 protein transduction or Sprouty2 stable transfection favors cancer phenotype. On the contrary suppression of Sprouty2 supports epithelial features in cancer cells and murine embryonic fibroblasts (MEFs) obtained from Sprouty2F/F-Villin CreERT2 mouse. However, requirement of Sprouty2 in CRC progression in vivo is not established. Effect of embryonic and postnatal Sprouty2 deletion in Sprouty2F/F-Villin Cre (embryonic deletion) and Sprouty2F/F-Villin CreERT2 mouse (tamoxifen dependent postnatal deletion), respectively, will be studied during AOM/DSS induced colonic carcinogenesis. We will also examine effect of Sprouty2 deletion in vivo on intestinal cell differentiation and lineage by utilizing both mice groups. To our knowledge, this is the first study to demonstrate the effect of in vivo deletion of SPRY2 on CRC progression and intestinal cell lineage. We have established our hypothesis based on our past and recent publications. The proposed study is a multi-prong approach to prepare us for a RO1 application.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Colon Cancer Chemoprevention and COX-2 Suppression by Ursodeoxycholic Acid
SPROUTY: PUTATIVE ONCOGENE IN COLORECTAL CANCER
Colon Cancer Chemoprevention and COX-2 Suppression by Ursodeoxycholic Acid
  • 批准号:
    8141038
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2011
  • 负责人:
    SHARAD KHARE
  • 依托单位:
Colon Cancer Chemoprevention and COX-2 Suppression by Ursodeoxycholic Acid
海外基金